Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16878| Title: | Calcitonin receptor expression in medullary thyroid carcinoma | Austin Authors: | Cappagli, Virginia;Potes, Catarina Soares;Ferreira, Luciana Bueno;Tavares, Catarina;Eloy, Catarina;Elisei, Rossella;Sobrinho-Simões, Manuel;Wookey, Peter J ;Soares, Paula | Affiliation: | Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Department of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal Department of Biomedicine - Experimental Biology Unit, Faculty of Medicine, University of Porto, Porto, Portugal Medical Faculty, University of Porto, Porto, Portugal Department of Pathology, Hospital de S. João, Porto, Portugal Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal |
Issue Date: | 13-Sep-2017 | Date: | 2017-09-13 | Publication information: | PeerJ 2017; online first: 13 September | Abstract: | BACKGROUND: Calcitonin expression is a well-established marker for medullary thyroid carcinoma (MTC); yet the role of calcitonin receptor (CTR), its seven-transmembrane G-protein coupled receptor, remains to be established in C-cells derived thyroid tumors. The aim of this work was to investigate CTR expression in MTC and to correlate such expression with clinicopathological features in order to evaluate its possible role as a prognostic indicator of disease aggressiveness and outcome. METHODS: Calcitonin receptor expression was analyzed in a series of 75 MTCs by immunohistochemistry, and by qPCR mRNA quantification in specimens from four patients. Statistical tests were used to evaluate the correlation between CTR expression and the clinicopathological and molecular characteristics of patients and tumors. RESULTS: Calcitonin receptor expression was detected in 62 out of 75 samples (82.7%), whereas 13 of the 75 samples (17.3%) were completely negative. CTR expression was significantly associated with expression of cytoplasmatic phosphatase and tensin homologue deleted on chromosome 10 and osteopontin, as well as with wild type RET/RAS genes and absence of tumor stroma, suggesting that CTR expression do not associate with clinicopathological signs of worse prognosis. DISCUSSION: Calcitonin receptor expression appears to be associated in MTC with more differentiated status of the neoplastic cells. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/16878 | DOI: | 10.7717/peerj.3778 | ORCID: | 0000-0002-3937-1621 | Journal: | PeerJ | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/28929017 | Type: | Journal Article | Subjects: | C-cells Calcitonin Calcitonin receptor Medullary thyroid carcinoma |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.